Allogene Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $-22 | $0 |
Gross Profit | -3,106 | -3,099 | -3,233 | -3,207 |
EBITDA | -56,819 | -56,484 | -56,182 | -62,986 |
EBIT | -59,925 | -59,583 | -59,415 | -66,193 |
Net Income | -50,943 | -59,733 | -59,939 | -66,293 |
Net Change In Cash | 0 | 0 | -22 | 0 |
Free Cash Flow | -39,074 | -53,028 | -36,955 | -44,544 |
Cash | 52,332 | 42,455 | 75,218 | 51,239 |
Basic Shares | 218,929 | 215,359 | 210,572 | 209,189 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $22 | $95 | $243 | $38,489 |
Gross Profit | 22 | -242,819 | 243 | 38,489 |
EBITDA | -243,327 | -313,066 | -321,154 | -245,338 |
EBIT | -256,966 | -327,265 | -335,449 | -255,792 |
Net Income | -257,590 | -327,265 | -329,815 | -244,837 |
Net Change In Cash | 22 | 95 | 243 | 38,489 |
Cost of Revenue | -9,194 | |||
Free Cash Flow | -200,994 | -239,249 | -225,710 | -206,258 |
Cash | 75,218 | 83,155 | 61,904 | 173,314 |
Basic Shares | 194,812 | 156,932 | 143,147 | 135,820 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.23 |
2025-03-31 | -$0.28 |
2024-12-31 | -$0.28 |
